Developing a new drug to help people with stimulant use disorders
Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder
This study is testing a new medication called 11h to help people struggling with stimulant use disorders, like cocaine addiction, and it aims to do this with fewer side effects than current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fannin Partners, LLC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10908017 on NIH RePORTER |
What this research studies
This research focuses on creating a new medication, known as 11h, aimed at treating stimulant use disorders (StUD), which have become increasingly common. The approach involves selectively inhibiting an inflammatory pathway in the brain, which may lead to fewer side effects compared to existing treatments. The drug has shown promising results in animal models, demonstrating effectiveness against substances like cocaine and exhibiting good safety and absorption characteristics. The goal is to advance this drug through early testing phases to assess its efficacy and safety in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with stimulant use disorders, particularly those who have not responded well to existing treatments.
Not a fit: Patients who do not have stimulant use disorders or those who are not seeking treatment for substance use issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with stimulant use disorders.
How similar studies have performed: Previous research has shown promise in developing targeted treatments for substance use disorders, but this specific approach using PDE4B inhibition is relatively novel.
Where this research is happening
Houston, United States
- Fannin Partners, LLC — Houston, United States (Active)
Researchers
- Principal investigator: Varadhachary, Atul — Fannin Partners, LLC
- Study coordinator: Varadhachary, Atul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.